The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $9.1 down -1.94% from its previous closing price of $9.28. In other words, the price has decreased by -$1.94 from its previous closing price. On the day, 5.89 million shares were traded. MLTX stock price reached its highest trading level at $9.64 during the session, while it also had its lowest trading level at $9.0.
Ratios:
For a deeper understanding of MoonLake Immunotherapeutics’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 16.65 and its Current Ratio is at 16.65. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On October 01, 2025, Goldman Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $7.
Wolfe Research Downgraded its Outperform to Underperform on September 30, 2025, while the target price for the stock was maintained at $2.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 29 ’25 when Chen Bihua sold 6,494,151 shares for $7.21 per share. The transaction valued at 46,827,628 led to the insider holds 2,000,000 shares of the business.
Chen Bihua sold 5,827 shares of MLTX for $40,556 on Sep 30 ’25. The Former 10% Owner now owns 1,994,173 shares after completing the transaction at $6.96 per share. On Jul 03 ’25, another insider, Moukheibir Catherine, who serves as the Director of the company, sold 23,500 shares for $48.79 each. As a result, the insider received 1,146,565 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 577862784 and an Enterprise Value of 232759760.
Stock Price History:
The Beta on a monthly basis for MLTX is 1.08, which has changed by -0.806383 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, MLTX has reached a high of $62.75, while it has fallen to a 52-week low of $5.95. The 50-Day Moving Average of the stock is -80.73%, while the 200-Day Moving Average is calculated to be -79.60%.
Shares Statistics:
For the past three months, MLTX has traded an average of 3.39M shares per day and 19367500 over the past ten days. A total of 63.47M shares are outstanding, with a floating share count of 55.14M. Insiders hold about 13.16% of the company’s shares, while institutions hold 81.69% stake in the company. Shares short for MLTX as of 1757894400 were 4948787 with a Short Ratio of 1.46, compared to 1755216000 on 5366017. Therefore, it implies a Short% of Shares Outstanding of 4948787 and a Short% of Float of 17.48.
Earnings Estimates
Currently, 7.0 analysts are dedicated to thoroughly evaluating and rating the performance of MoonLake Immunotherapeutics (MLTX) in the stock market.The consensus estimate for the next quarter is -$0.92, with high estimates of -$0.8 and low estimates of -$1.03.
Analysts are recommending an EPS of between -$3.17 and -$3.56 for the fiscal current year, implying an average EPS of -$3.36. EPS for the following year is -$3.64, with 9.0 analysts recommending between -$1.83 and -$4.49.
